Cargando…

P052: Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL)

Detalles Bibliográficos
Autores principales:	Xagoraris, Ioanna, Stathopoulou, Konstantina, Renken, Stefanie, Lundqvist, Andreas, Claret, Francois Xavier, Drakos, Elias, Rassidakis, Georgios Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Genomics, Biology & Microenvironment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642059/ http://dx.doi.org/10.1097/01.HS9.0000890776.31358.d3

Ejemplares similares

P053: The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)
por: Xagoraris, Ioanna, et al.
Publicado: (2022)

PB2171: THE NOVEL CSN5/JAB1 INHIBITOR CSN5I-3 SUPPRESSES CELL GROWTH AND UPREGULATES GENE EXPRESSION OF TYPE-I INTERFERONS (IFN) IN ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)
por: Xagoraris, I., et al.
Publicado: (2022)

P051: Serum procalcitonin levels in newly diagnosed classical Hodgkin Lymphoma (cHL): Correlation with other inflammatory biomarkers
por: Piperidou, Alexia, et al.
Publicado: (2022)

P032: Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.
por: Mulder, Tom A., et al.
Publicado: (2022)

Stat3 Contributes to Cancer Progression by Regulating Jab1/Csn5 Expression
por: Pan, Yunbao, et al.
Publicado: (2016)

P1304: THE NOVEL TUMOR SUPPRESSOR SAMHD1 CONTRIBUTES TO ANTI-TUMOR RESPONSES IN A CGAS-STING-DEPENDENT OR INDEPENDENT PATHWAY IN HODGKIN LYMPHOMA (HL)
por: Xagoraris, I., et al.
Publicado: (2022)

JAB1/CSN5: a new player in cell cycle control and cancer
por: Shackleford, Terry J, et al.
Publicado: (2010)

Sting Is Commonly and Differentially Expressed in T- and Nk-Cell but Not B-Cell Non-Hodgkin Lymphomas
por: Xagoraris, Ioanna, et al.
Publicado: (2022)

T026: Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma
por: Karihtala, Kristiina, et al.
Publicado: (2022)

P038: HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin lymphoma
por: Müller-Meinhard, Berit, et al.
Publicado: (2022)

P054: The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma
por: Visentin, Andrea, et al.
Publicado: (2022)

P048: Predictors of risk of relapse in classic Hodgkin lymphoma by flow cytometry
por: Fromm, Jonathan, et al.
Publicado: (2022)

P035: CRISPR/Cas9-mediated knockout reveals an important role of CD30 in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma
por: Kilian, Annika L., et al.
Publicado: (2022)

Suppression of Jab1/CSN5 induces radiation- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways
por: Pan, Yunbao, et al.
Publicado: (2012)

P044: PIM kinases support protumoral and immunosuppressive phenotype and functions of macrophages in classical Hodgkin Lymphoma
por: Szydłowski, Maciej, et al.
Publicado: (2022)

Impact of Tumour Epstein–Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL
por: Nohtani, Mahdi, et al.
Publicado: (2022)

P049: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma
por: Seifert, Nicole, et al.
Publicado: (2022)

P034: Correlation between MTV, TLG and Serum TARC Concentration in Classical Hodgkin Lymphoma during First-Line Treatment
por: Romano, Ilaria, et al.
Publicado: (2022)

P047: Predictive role of the Hodgkin lymphoma-associated cytokines: a prospective study of the Czech Hodgkin Study Group
por: Prochazka, Vit, et al.
Publicado: (2022)

Identification of a seven-long non-coding RNA signature associated with Jab1/CSN5 in predicting hepatocellular carcinoma
por: Ma, Weijie, et al.
Publicado: (2021)

P043: Molecular pathogenesis of Hodgkin lymphoma
por: Beeck, Lilian, et al.
Publicado: (2022)

An overview of cancer/testis antigens expression in classical Hodgkin's lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients
por: Inaoka, Riguel J, et al.
Publicado: (2011)

P055: Validation of the tumor cell-specific rearranged IgG-encoding circulating cell-free DNA for the treatment response monitoring in patients with classic Hodgkin lymphoma
por: Buhtoiarov, Ilia, et al.
Publicado: (2022)

P045: Plasma proteome profiling of cardiotoxicity in patients with Hodgkin lymphoma
por: Ulfstedt, Johan Mattsson, et al.
Publicado: (2022)

Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells
por: Shackleford, Terry J, et al.
Publicado: (2011)

P046: Preclinical evaluation of novel repurposed drug combinations in Hodgkin lymphoma
por: Lohmann, Mia, et al.
Publicado: (2022)

P040: LINE-1 reverse transcriptase activity in Hodgkin lymphoma cells
por: Wadel, Annika, et al.
Publicado: (2022)

P042: Metabolic regulation of adaptive response to arginine deprivation in Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2022)

T028: Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade
por: Paczkowska, Julia, et al.
Publicado: (2022)

Hsa-miR-24-3p Increases Nasopharyngeal Carcinoma Radiosensitivity by Targeting Both the 3’UTR and 5’UTR of Jab1/CSN5
por: Wang, Sumei, et al.
Publicado: (2016)

Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087
por: Chen, Robert, et al.
Publicado: (2015)

The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19
por: Rajabto, Wulyo, et al.
Publicado: (2022)

P033: Clinical significance of the severity of THRLBCL-like areas in nodular lymphocyte predominant Hodgkin lymphoma
por: Shupletsova, Irirna, et al.
Publicado: (2022)

P056: Variants of the transcription factor ONECUT2 regulate gene expression in Hodgkin Lymphoma cells
por: Lein, Patricia, et al.
Publicado: (2022)

P030: Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study i
por: Romano, Alessandra, et al.
Publicado: (2022)

P036: Detection of recurrent somatic variants in cell-free DNA as a tool for disease monitoring in Hodgkin lymphoma
por: Grohmann, Jan, et al.
Publicado: (2022)

T027: High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years
por: Diepstra, Arjan, et al.
Publicado: (2022)

P039: HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin lymphoma
por: Grund, Johanna, et al.
Publicado: (2022)

P031: CD4+ T cells in close proximity to Hodgkin-Reed Sternberg cells are antigen experienced, polyclonal and display an exhausted phenotype
por: Veldman, Johanna, et al.
Publicado: (2022)

P037: High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma
por: Mammadova, Laman, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_frh0nji2p4p0ljqke4kp29s8hl